Asimilar Group Plc

AQSE Growth Market -
The Company's Investing Policy is to invest in businesses which have some or all of the following characteristics: strong management with a proven track record; ready for investment without the need for material re-structuring by the Company; via an injection of new finances or specialist management, the Company can enhance the prospects and therefore the future value of the investment; able to benefit from the Directors existing network of contacts; and the potential to deliver significant returns for the Company. Asimilar Group Plc invests in the technology and software sectors and focuses primarily on opportunities in the Big Data, Machine Learning, Telematics and Internet of Things areas.
Symbol Ccy Code Bid Ask Share Price (Mid) Previous Close Volume Last Traded
ASLR GBX 6 7 6.5 6.5 -

MiFID II compliant pre- and post-trade transaction data is available here. The data is delayed by at least 15 minutes and will be refreshed every 15 minutes. Publication of trades in equity securities that are large in scale compared to normal market size and illiquid non-equity securities may be delayed if the trade is eligible for deferred publication in accordance with the trading rules of Aquis Stock Exchange and MiFIR. Further details as to when the publication of a trade may be deferred are set out in the trading rules which are available here.

Key Information

Market Cap: £8,222,378
Inst Type:Ordinaries
Tradable securities in issue:126,498,125
Sector:Equity Investment Instruments
% daily price change:0.00%

Latest Trades

There are currently no trades.


Business Address

Asimilar Group Plc, 4 More London Riverside, London, SE1 2AU, United Kingdom.


Registered Address

4 More London Riverside, London, SE1 2AU, United Kingdom.


Corporate Adviser

Oberon Capital, Nightingale House, 65 Curzon Street, London, United Kingdom.


Phone: +44 (0) 20 3179 5300


Share Registrars Ltd, 3 The Millennium Centre, Crosby Way, Farnham, Surrey, GU9 7XX, United Kingdom.


Phone: +44 (0) 1252 821390


There is no research available.